Please assess the completion status of the following clinical trial:

Trial Title: Study of Combination Therapy of Gliclazide MR and Basal Insulin Versus Insulin Monotherapy to Treat Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Male or female with type 2 diabetes mellitus~2. 35 years old≤age≤65 years old~3. 19kg/m2≤BMI≤32kg/m2~4. Uncontrolled blood glycemia (FPG≥7.0mmol/L and 7.5%\<HbA1c≤10%) after oral antidiabetes drugs treatment for more than 3 months~5. Treated by diet controlling, 1 secretagogue agent and another oral antidiabetes drug, with the daily dosage of the secretagogue agent not more than 50% of its maximum~6. Not participated in other clinical studies within the past 3 months~7. Well know this study and sign the informed consent form~Exclusion criteria:~1. Unable to sign the informed consent form~2. Treated by insulin, even transient usage within the past 1 year~3. Type 1 diabetes mellitus~4. Abnormal condition of gastrointestinal tract against the absorption of oral drugs~5. Insufficient of liver and kidney function: ALT≥2.5 times of the upper limit of the normal value range and serum creatinine≥the upper limit of the normal value range~6. Encountered the cardiovascular events such as the angina pectoris, myocardial infarction, severe ventricular arrhythmia, cerebral hemorrhage, cerebral infarction, heart failure ect. within the past half year~7. Usage of the other hormone medicines such as cortical hormone, immunosuppressive agents or cytotoxic drugs within the past 2 months~8. psychotic~9. Allergic history to sulfonylurea drugs~10. Diabetic coma or diabetic ketoacidosis~11. In use of the miconazole~12. Pregnancy or breeding women

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Combination therapy (Type: EXPERIMENTAL): The subjects allocated into this arm will receive the combination therapy of oral administration of 60\~120mg Gliclazide MR (Diamicron MR) and subcutaneous injection of basal insulin (Insulin Glargine Injection, Lantus) once daily for 3 months
- monotherapy (Type: ACTIVE_COMPARATOR): The patients allocated into this arm will receive the monotherapy of subcutaneous injection of premixed insulin (Biosynthetic Human Insulin Injection, Novolin 30R) twice daily for 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).